Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF), an Edmonton-based life sciences services and technology company, has announced a new banking partnership with ATB Financial that provides $600,000 in combined credit facilities. The arrangement includes a $500,000 revolving operating line of credit and a $100,000 corporate credit card facility. The non-dilutive working capital is intended to support the commercial rollout of the company's InnovoTEST™ Hazardous Drug Wipe Testing Kits and the expansion of its contract research and laboratory testing services, making this announcement of immediate relevance to investors monitoring the company's growth trajectory.

Key Points

  • Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) is an Edmonton-based applied microbiology and regulated laboratory services company
  • The company has established a new banking relationship with ATB Financial, securing $600,000 in total credit facilities
  • Facilities comprise a $500,000 revolving operating line of credit and a $100,000 corporate credit card facility
  • Investors may watch for progress in the InnovoTEST™ commercial rollout and signs of improved operational efficiency from banking consolidation

Structure of the ATB Financial Credit Arrangement

The $600,000 in credit facilities consists of two components: a $500,000 revolving operating line of credit and a $100,000 corporate credit card facility. Innovotech describes the arrangement as non-dilutive, meaning existing shareholders are not subject to equity dilution as a result of this financing. The company states the facilities offer flexible working capital access suited to its current stage of commercial and operational development. The immediate share price impact was not clear from available public information.

InnovoTEST™ Rollout and Laboratory Services Expansion

Innovotech identifies two primary uses for the credit facilities: supporting the commercial rollout of its InnovoTEST™ Hazardous Drug Wipe Testing Kits and expanding its contract research and laboratory testing services. The company serves medical device, pharmaceutical, and healthcare clients in Canada and internationally, and operates ISO-certified and GMP-accredited laboratories. Its portfolio also includes the MBEC Assay® platform for antimicrobial and antibiotic testing, positioning the new facilities within a broader scientific services business.

Banking Consolidation Expected to Reduce Costs and Complexity

As part of the transition to ATB Financial, Innovotech will consolidate its day-to-day banking by closing legacy accounts and smaller facilities. The company states it expects this consolidation to reduce administrative effort and banking costs while giving management a clearer, single view of its cash position. CEO Craig Milne commented that the arrangement fits the company's growing Alberta life sciences profile and that a single banking relationship makes Innovotech "a simpler, more efficient company," according to the release.